Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 200, Issue 1, Pages 64-69Publisher
WILEY
DOI: 10.1111/bjh.18469
Keywords
AML; CAR; cell therapy; cytokine-induced killer lymphocytes; HSC transplantation
Categories
Ask authors/readers for more resources
This study explored the feasibility, anti-leukaemic activity, and alloreactive risk of genetically redirected CIK (fcCAR.CIK) generated from full-donor chimaeric patients. The results showed that fcCAR.CIK exhibited intense preclinical anti-leukaemic activity without enhancing the risk of graft-versus-host disease, supporting the potential use of fcCAR.CIK as an alternative to conventional donor lymphocyte infusion following haematopoietic cell transplantation.
Cytokine-induced killer lymphocytes (CIK) are a promising alternative to conventional donor lymphocyte infusion (DLI), following allogeneic haematopoietic cell transplantation (HCT), due to their intrinsic anti-tumour activity and reduced risk of graft-versus-host disease (GVHD). We explored the feasibility, anti-leukaemic activity and alloreactive risk of CIK generated from full-donor chimaeric (fc) patients and genetically redirected by a chimeric antigen receptor (CAR) (fcCAR.CIK) against the leukaemic target CD44v6. fcCAR.CIK were successfully ex-vivo expanded from leukaemic patients in complete remission after HCT confirming their intense preclinical anti-leukaemic activity without enhancing the alloreactivity across human leukocyte antigen (HLA) barriers. Our study provides translational bases to support clinical studies with fcCAR.CIK, a sort of biological bridge between the autologous and allogeneic sources, as alternative DLI following HCT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available